Ratings by UBS (David Dai)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/16/2026 | Celldex Therapeutics | CLDX | Maintain | Buy (Buy) |
|
Details | ||
| 6/10/2026 | Celldex Therapeutics | CLDX | Maintain | Buy (Buy) |
|
Details | ||
| 6/10/2026 | Nuvalent | NUVL | Downgrade | Neutral (Buy) |
88.49 (123.42) |
39.47% | Details | |
| 6/9/2026 | Nurix | NRIX | Maintain | Buy (Buy) |
|
Details | ||
| 5/18/2026 | CG Oncology | CGON | Maintain | Buy (Buy) |
|
Details | ||
| 5/14/2026 | Engene Holdings Inc. | ENGN | Maintain | Neutral (Neutral) |
|
Details | ||
| 5/13/2026 | Syndax Pharmaceuticals | SNDX | Maintain | Buy (Buy) |
|
Details | ||
| 4/28/2026 | CG Oncology | CGON | Maintain | Buy (Buy) |
|
Details | ||
| 4/17/2026 | Summit Therapeutics plc | SMMT | Maintain | Buy (Buy) |
|
Details | ||
| 4/15/2026 | Janux Therapeutics | JANX | Downgrade | Neutral (Buy) |
14.90 (14.34) |
-3.76% | Details | |
| 3/26/2026 | CG Oncology | CGON | Maintain | Buy (Buy) |
|
Details | ||
| 3/23/2026 | Jasper Therapeutics | JSPR | New Coverage | Neutral (N/A) |
1.23 (0.50) |
-59.35% | Details | |
| 3/23/2026 | Engene Holdings Inc. | ENGN | Maintain | Neutral (N/A) |
|
Details | ||
| 3/18/2026 | Perspective Therapeutics Inc | CATX | Maintain | Buy (Buy) |
|
Details | ||
| 3/13/2026 | Kura Oncology | KURA | Maintain | Buy (Buy) |
|
Details | ||
| 3/5/2026 | Iovanace Biotherapeutics | IOVA | Maintain | Neutral (Neutral) |
|
Details | ||
| 3/3/2026 | Kymera Therapeutics | KYMR | Maintain | Buy (Buy) |
|
Details | ||
| 12/17/2025 | Nuvalent | NUVL | Maintain | Buy (Buy) |
|
Details | ||
| 12/2/2025 | Janux Therapeutics | JANX | Maintain | Buy (Buy) |
|
Details | ||
| 11/21/2025 | Moderna | MRNA | Maintain | Buy (Buy) |
|
Details | ||
| 11/21/2025 | Perspective Therapeutics Inc | CATX | Maintain | Buy (Buy) |
|
Details | ||
| 11/14/2025 | Kura Oncology | KURA | Maintain | Buy (Buy) |
|
Details | ||
| 11/4/2025 | Syndax Pharmaceuticals | SNDX | Maintain | Buy (Buy) |
|
Details | ||
| 10/31/2025 | Nuvalent | NUVL | Maintain | Buy (N/A) |
|
Details | ||
| 10/20/2025 | Summit Therapeutics plc | SMMT | Maintain | Buy (Buy) |
|
Details | ||
| 10/10/2025 | Summit Therapeutics plc | SMMT | Maintain | Buy (Buy) |
|
Details | ||
| 9/30/2025 | Merus N.V. | MRUS | Downgrade | Neutral (Buy) |
68.89 (90.00) |
30.64% | Details | |
| 9/23/2025 | Ideaya Biosciences | IDYA | Maintain | Buy (Buy) |
|
Details | ||
| 8/22/2025 | Summit Therapeutics plc | SMMT | Maintain | Buy (Buy) |
|
Details | ||
| 8/22/2025 | Perspective Therapeutics Inc | CATX | Maintain | Buy (Buy) |
|
Details | ||
| 7/15/2025 | Syndax Pharmaceuticals | SNDX | Maintain | Buy (N/A) |
|
Details | ||
| 7/10/2025 | Nurix | NRIX | Maintain | Buy (N/A) |
|
Details | ||
| 7/1/2025 | Summit Therapeutics plc | SMMT | New Coverage | Buy (N/A) |
20.60 (14.28) |
-30.68% | Details | |
| 6/25/2025 | Nuvalent | NUVL | Maintain | Buy (Buy) |
|
Details | ||
| 6/13/2025 | Nurix | NRIX | Maintain | Buy (Buy) |
|
Details | ||
| 6/5/2025 | Blueprint Medicines | BPMC | Maintain | Neutral (Neutral) |
|
Details | ||
| 5/16/2025 | Iovanace Biotherapeutics | IOVA | Downgrade | Neutral (Buy) |
1.70 (4.06) |
138.82% | Details | |
| 5/12/2025 | Cullinan Oncology Inc. | CGEM | Maintain | Buy (Buy) |
|
Details | ||
| 4/29/2025 | CG Oncology | CGON | Maintain | Buy (Buy) |
|
Details | ||
| 4/10/2025 | Nurix | NRIX | Maintain | Buy (Buy) |
|
Details | ||
| 3/14/2025 | Nuvalent | NUVL | Upgrade | Buy (Neutral) |
72.52 (88.49) |
22.02% | Details | |
| 3/6/2025 | Kura Oncology | KURA | Maintain | Buy (Buy) |
|
Details | ||
| 10/24/2024 | Blueprint Medicines | BPMC | New Coverage | Neutral (N/A) |
86.47 (129.46) |
49.72% | Details | |
| 10/24/2024 | Kura Oncology | KURA | New Coverage | Buy (N/A) |
17.37 (10.36) |
-40.36% | Details | |
| 10/24/2024 | Merus N.V. | MRUS | New Coverage | Buy (N/A) |
53.19 (68.89) |
29.52% | Details | |
| 10/24/2024 | Janux Therapeutics | JANX | New Coverage | Buy (N/A) |
52.80 (14.90) |
-71.78% | Details | |
| 10/24/2024 | Iovanace Biotherapeutics | IOVA | New Coverage | Buy (N/A) |
9.96 (4.06) |
-59.24% | Details | |
| 10/24/2024 | Ideaya Biosciences | IDYA | New Coverage | Buy (N/A) |
30.22 (34.94) |
15.62% | Details | |
| 10/24/2024 | Immunocore Holdings | IMCR | New Coverage | Sell (N/A) |
33.31 (32.75) |
-1.68% | Details | |
| 10/24/2024 | Perspective Therapeutics Inc | CATX | New Coverage | Buy (N/A) |
12.39 (3.05) |
-75.38% | Details | |
| 10/24/2024 | CG Oncology | CGON | New Coverage | Buy (N/A) |
36.98 (66.25) |
79.15% | Details | |
| 10/24/2024 | Cullinan Oncology Inc. | CGEM | New Coverage | Buy (N/A) |
15.95 (17.30) |
8.46% | Details | |
| 10/24/2024 | Nurix | NRIX | New Coverage | Buy (N/A) |
25.52 (18.65) |
-26.92% | Details | |
| 10/24/2024 | Nuvalent | NUVL | New Coverage | Neutral (N/A) |
102.51 (72.52) |
-29.26% | Details | |
| 10/24/2024 | Syndax Pharmaceuticals | SNDX | New Coverage | Buy (N/A) |
19.16 (19.32) |
0.84% | Details |
